Last reviewed · How we verify
Prednisone 15 mg
Prednisone 15 mg is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 1 development. Also known as: Prednisone.
Prednisone 15 mg is a small molecule used to treat various conditions, including Leukemia, Lymphoma, Myelofibrosis, Lupus Erythematosus, and Acute Lymphoblastic Leukemia. It is often used in combination with other medications such as cytarabine, decitabine, and doxorubicin hydrochloride in clinical trials.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Merck Sharp & Dohme LLC is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Prednisone 15 mg |
|---|---|
| Also known as | Prednisone |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- INFUSION RELATED REACTION
- NAUSEA
- NEUTROPENIA
- FATIGUE
- CONSTIPATION
- COUGH
- DIARRHOEA
- NASOPHARYNGITIS
- VOMITING
- PYREXIA
- ARTHRALGIA
- UPPER RESPIRATORY TRACT INFECTION
Key clinical trials
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma (PHASE1, PHASE2)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- LBL-2016 for Children or Adolescents in China (PHASE3)
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (PHASE2)
- Orelabrutinib in the Treatment of Relapsed/Refractory AIHA (PHASE2)
- Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares (PHASE4)
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma (PHASE1)
- Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisone 15 mg CI brief — competitive landscape report
- Prednisone 15 mg updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Prednisone 15 mg
What is Prednisone 15 mg?
Who makes Prednisone 15 mg?
Is Prednisone 15 mg also known as anything else?
What development phase is Prednisone 15 mg in?
What are the side effects of Prednisone 15 mg?
Related
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Also known as: Prednisone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing